| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
TNIK-IN-5 targets Traf2- and Nck-interacting protein kinase (TNIK), a serine/threonine kinase that is a key downstream effector of the Wnt signaling pathway. TNIK is involved in the regulation of β-catenin transcriptional activity and plays a critical role in colorectal cancer pathogenesis. The compound inhibits TNIK with an IC50 of 0.05 μM. By inhibiting TNIK, TNIK-IN-5 efficiently suppresses Wnt signaling in intact cells, making it a valuable tool for studying TNIK's role in oncogenesis.
|
|---|---|
| ln Vitro |
TNIK-IN-5 (compound 8g) (1.25-5 μM; 48 hours) substantially and dose-dependently reduced the growth of HCT116 cells [1]. The HCT116 cell migration is greatly inhibited by TNIK-IN-5 (1 μM; 24, 48 hours) [1]. TNIK-IN-5 (10–40 μM; 48 hours) dramatically lowers the expression of Wnt target gene products, such as Axin2 and c-Myc, and concentration-dependently suppresses the protein levels of TCF-4 and β-catenin in the nucleus [1].
TNIK-IN-5 inhibits TNIK with an IC50 of 0.05 μM. The compound efficiently inhibits Wnt signaling in intact cells. It shows excellent in vitro anti-colorectal cancer activity. The compound's specificity and effectiveness make it a valuable tool for studying the mechanistic role of TNIK in oncogenesis and for developing therapeutic strategies targeting TNIK-driven cancers. TNIK-IN-5 demonstrates potent inhibition of Wnt signaling, a pathway frequently dysregulated in colorectal cancer. |
| ln Vivo |
In vivo activity data for TNIK-IN-5 are not extensively detailed in the available literature. The compound has shown promising potential in cancer research, particularly in tumors with aberrant Wnt signaling. Given its potent inhibition of TNIK and Wnt signaling in vitro, it is expected to exhibit antitumor activity in animal models of colorectal cancer and other Wnt-driven tumors. However, specific in vivo efficacy studies and animal model data are not specified in the public domain. The compound is intended for research use.
|
| Enzyme Assay |
The in vitro enzyme assay for TNIK-IN-5 typically involves measuring the inhibition of TNIK kinase activity using a kinase assay. Recombinant TNIK enzyme is incubated with varying concentrations of TNIK-IN-5 (typically 0.001-100 μM) in the presence of ATP and a peptide substrate. The kinase activity is measured by monitoring the phosphorylation of the substrate using a radioactive (33P-ATP) or fluorescence-based detection method. The IC50 value is determined by plotting the percentage of inhibition against compound concentration. The compound is dissolved in DMSO and diluted in assay buffer.
|
| Cell Assay |
Cell proliferation experiment
Cell Types: HCT116 cells [1] Tested Concentrations: 1.25 μM, 2.5 μM, 5 μM Incubation Duration: 48 hrs (hours) Experimental Results: Dramatically inhibited cell proliferation in a dose-dependent manner. In vitro cellular assays for TNIK-IN-5 typically involve treating colorectal cancer cell lines (such as HCT116, SW480, or DLD-1) with the compound at concentrations ranging from 0.001 to 10 μM for 24-72 hours. Wnt signaling activity is assessed using TOPFlash/FOPFlash reporter assays or by measuring the expression of Wnt target genes (such as AXIN2, MYC, and CCND1) by qPCR. Cell viability and proliferation are evaluated using MTT, CCK-8, or CellTiter-Glo assays. The compound is dissolved in DMSO as a stock solution and diluted in cell culture medium. |
| Animal Protocol |
In vivo animal studies for TNIK-IN-5 are not extensively documented. For potential in vivo applications, the compound could be administered to mice via oral gavage or intraperitoneal injection at doses determined from preliminary studies. Colorectal cancer xenograft models using Wnt-driven cell lines could be used to evaluate antitumor efficacy. Tumor growth is monitored by caliper measurements, and Wnt signaling activity in tumors is assessed by measuring target gene expression. The compound's pharmacokinetics and pharmacodynamics would be evaluated in these models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TNIK-IN-5 are not extensively documented. The compound has a molecular weight of 371.38 g/mol and formula C22H17N3O3. It has a purity of 99.75%. The recommended storage conditions are typically -20°C for powder and -80°C for solvent. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination. The compound is soluble in DMSO and other organic solvents.
|
| Toxicity/Toxicokinetics |
Toxicity data for TNIK-IN-5 are not extensively reported. The compound is intended for research use only and is not approved for human therapeutic applications. Standard preclinical toxicity assessments would include acute toxicity studies in rodents, repeated-dose toxicity studies, and assessment of off-target effects. As a TNIK inhibitor targeting the Wnt signaling pathway, the compound may affect normal Wnt-dependent processes, which could contribute to potential toxicity. Appropriate safety precautions should be taken when handling.
|
| References | |
| Additional Infomation |
TNIK-IN-5 (CAS 2754265-66-0) is a potent inhibitor of TNIK with an IC50 of 0.05 μM. It has a molecular weight of 371.38 g/mol and formula C22H17N3O3. The compound efficiently inhibits Wnt signaling in intact cells and shows excellent in vitro anti-colorectal cancer activity. TNIK-IN-5 is used in research on Wnt signaling and colorectal cancer biology. It is also known as 3-(3-Methoxybenzyl)-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)benzo[d]oxazol-2(3H)-one. The compound is not approved for clinical use.
|
| Molecular Formula |
C22H17N3O3
|
|---|---|
| Molecular Weight |
371.39
|
| Exact Mass |
371.127
|
| CAS # |
2754265-66-0
|
| PubChem CID |
163322020
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
573
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC(=C1)CN2C3=C(C=C(C=C3)C4=CN=C5C(=C4)C=CN5)OC2=O
|
| InChi Key |
DRHILHIKLGEWOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H17N3O3/c1-27-18-4-2-3-14(9-18)13-25-19-6-5-15(11-20(19)28-22(25)26)17-10-16-7-8-23-21(16)24-12-17/h2-12H,13H2,1H3,(H,23,24)
|
| Chemical Name |
3-[(3-methoxyphenyl)methyl]-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-benzoxazol-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6926 mL | 13.4629 mL | 26.9259 mL | |
| 5 mM | 0.5385 mL | 2.6926 mL | 5.3852 mL | |
| 10 mM | 0.2693 mL | 1.3463 mL | 2.6926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
